The Clinical Pharmacology of Etoposide and Teniposide

Intercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II.

1984 • 896 citations

Cisplatin : current status and new developments

1980 • 746 citations

Role of topoisomerase II in mediating epipodophyllotoxin-induced DNA cleavage.

1984 • 463 citations

Etoposide (VP-16–213)

1985 • 361 citations

Interaction of drugs with microtubule proteins.

1974 • 349 citations

Nucleoside transport in mammalian cells. Inhibition by colchicine

1972 • 323 citations

The Biochemical Events of Mitosis. II. The in Vivo and in Vitro Binding of Colchicine in Grasshopper Embryos and Its Possible Relation to Inhibition of Mitosis^*

1967 • 291 citations

DNA damage as a basis for 4'-demethylepipodophyllotoxin-9-(4,6-O-ethylidene-beta-D-glucopyranoside) (etoposide) cytotoxicity.

1983 • 223 citations

Effect of VP-16-213 on the intracellular degradation of DNA in HeLa cells

1976 • 197 citations

Comparison of cytotoxicity and DNA breakage activity of congeners of podophyllotoxin including VP16-213 and VM26: a quantitative structure-activity relationship

1984 • 188 citations

Effects of podophyllotoxin and VP-16-213 on microtubule assembly in vitro and nucleoside transport in HeLa cells

1976 • 187 citations

Activity of a new glycosidic lignan derivative (VP 16-213) related to podophyllotoxin in experimental tumors

1973 • 184 citations

The Biological Effects and the Chemical Composition of Podophyllin. A Review

1954 • 181 citations

VP-16-213 monotherapy for remission induction of small cell lung cancer: a randomized trial using three dosage schedules.

1978 • 166 citations

Characterization of acquired epipodophyllotoxin resistance in a Chinese hamster ovary cell line: loss of drug-stimulated DNA cleavage activity.

1986 • 165 citations

Mitosis-inhibiting natural products. 24. Synthesis and antimitotic activity of glycosidic lignan derivatives related to podophyllotoxin

1971 • 163 citations

OVERVIEW OF DRUG‐PROTEIN BINDING

1973 • 161 citations

Etoposide (VP-16-213)

1979 • 151 citations

Pharmacokinetics of high-dose etoposide (VP-16-213) administered to cancer patients.

1984 • 149 citations

SCHEDULE DEPENDENCY OF THE ANTILEUKEMIC ACTIVITY OF THE PODOPHYLLOTOXIN‐DERIVATIVE VP 16–213 (NSC‐141540) IN L1210 LEUKEMIA

1973 • 148 citations

The podophyllotoxin derivatives VP16-213 and VM26

1982 • 146 citations

Structure-activity study of the inhibition of microtubule assembly in vitro by podophyllotoxin and its congeners.

1978 • 142 citations

Therapeutic trials with VP-16-213 and VM-26: active agents in small cell lung cancer, non-Hodgkin's lymphomas, and other malignancies.

1979 • 142 citations

Identification of DNA topoisomerase II as an intracellular target of antitumor epipodophyllotoxins in simian virus 40-infected monkey cells.

1985 • 136 citations

Phorbol myristate acetate stimulates microtubule and 10-nm filament extension and lysosome redistribution in mouse macrophages.

1980 • 135 citations

Cytofluorometric studies on the action of podophyllotoxin and epipodophyllotoxins (VM-26, VP-16-213) on the cell cycle traverse of human lymphoblasts.

1975 • 133 citations

4′-Demethyl-epipodophyllotoxin thenylidene glucoside (VM 26), a podophyllum compound with a new mechanism of action

1970 • 130 citations

BIOCHEMICAL AND PHARMACOLOGICAL PROPERTIES OF MICROTUBULES

1974 • 127 citations

VM 26 and VP 16–213: A comparative analysis

1977 • 122 citations

Pharmacokinetics of VP16-213 given by different administration methods

1982 • 121 citations

Drug Interactions with Warfarin

1983 • 119 citations

Mutagenic responses of thirteen anticancer drugs on mutation induction at multiple genetic loci and on sister chromatid exchanges in Chinese hamster ovary cells.

1983 • 117 citations

Effects of the epipodophyllotoxin VP-16-213 on cell cycle traverse, DNA synthesis, and DNA strand size in cultures of human leukemic lymphoblasts.

1983 • 114 citations

The Similarity of the Effect of Podophyllin and Colchicine and Their Use in the Treatment of Condylomata Acuminata

1946 • 114 citations

Conformational analysis of podophyllotoxin and its congeners. Structure-activity relationship in microtubule assembly

1979 • 113 citations

In vivo resistance towards anthracyclines, etoposide, and cis-diamminedichloroplatinum(II).

1982 • 109 citations

Comparison of the human pharmacokinetics of VM-26 and VP-16, two antineoplastic epipodophyllotoxin glucopyranoside derivatives

1975 • 109 citations

Pharmacokinetics of teniposide (VM26) and etoposide (VP16-213) in children with cancer

1982 • 107 citations

Inhibition of epipodophyllotoxin cytotoxicity by interference with topoisomerase-mediated DNA cleavage

1985 • 104 citations

Survival and cycle-progression delay of human lymphoma cells in vitro exposed to VP-16-213.

1976 • 102 citations

Etoposide: A Semisynthetic Epipodophyllotoxin Chemistry, Pharmacology, Pharmacokinetics, Adverse Effects and Use as an Antineoplastic Agent

1984 • 99 citations

A clinical trial of the oral form of 4′-demethyl-epipodophyllotoxin-β-D ethylidene glucoside (NSC 141540) VP 16–213

1975 • 97 citations

Cross-resistance to intercalating agents in an epipodophyllotoxin-resistant Chinese hamster ovary cell line: evidence for a common intracellular target.

1986 • 93 citations

Analysis of the anticancer drugs VP 16-213 and VM 26 and their metabolites by high-performance liquid chromatography

1980 • 90 citations

Podophyllotoxin derivative VP 16-213

1979 • 86 citations

Response of L1210 to combinations of cytosine arabinoside and VM-26 or VP16-213

1975 • 85 citations

Bioavailability and pharmacokinetics of etoposide (VP-16).

1985 • 85 citations

Phase II study of VP-16-213 in childhood malignant disease: a Children's Cancer Study Group Report.

1979 • 83 citations

Book Review: Etoposide (VP-16): Current Status and New Developments

1985 • 82 citations

Phase I clinical and pharmacological study of 72-hour continuous infusion of etoposide in patients with advanced cancer.

1987 • 80 citations

VP-16-213 (etoposide): The mandrake root from Issyk-Kul

1982 • 79 citations

Effect of an epipodophyllotoxin derivative (VP 16-213) on macromolecular synthesis and mitosis in mastocytoma cells in vitro.

1974 • 77 citations

Penetration of VP 16-213 into cerebrospinal fluid after high-dose intravenous administration.

1984 • 77 citations

Penetration of VP-16 (etoposide) into human intracerebral and extracerebral tumors

1984 • 77 citations

Cell cycle stage-dependent induction of G2 phase arrest by different antitumor agents

1978 • 71 citations

Pharmacokinetic Consequences of Drug Displacement from Blood and Tissue Proteins

1984 • 68 citations

Genetic, biochemical, and cross-resistance studies with mutants of Chinese hamster ovary cells resistant to the anticancer drugs, VM-26 and VP16-213.

1983 • 68 citations

High-Performance Liquid Chromatographic Analysis of the Semisynthetic Epipodophyllotoxins Teniposide and Etoposide Using Electrochemical Detection

1984 • 67 citations

Bioavailability, pharmacokinetics, and clinical effects of an oral preparation of etoposide.

1985 • 66 citations

Variable bioavailability following repeated oral doses of etoposide

1985 • 65 citations

EPEG, a new antineoplastic epipodophyllotoxin

1975 • 64 citations

Pharmacokinetics of etoposide (VP16) in children and adolescents with refractory solid tumors.

1984 • 63 citations

Teniposide: a review of 12 years of experience.

1984 • 60 citations

The clinical pharmacology of VM26 and VP16-213

1982 • 60 citations

Verapamil potentiation of VP-16-213 in acute lymphatic leukemia and reversal of pleiotropic drug resistance

1986 • 60 citations

VM-26 and cytosine arabinoside combination chemotherapy for initial induction failures in childhood lymphocytic leukemia

1980 • 59 citations

Nonenolizable podophyllotoxin derivatives

1977 • 58 citations

Pharmacokinetics of high dose etoposide (VP 16–213)

1986 • 57 citations

High-performance liquid chromatography determination of 4′-demethyl-epipodophyllotoxin-9-(4,6-O-ethylidene β-d-glucopyranoside) (VP 16-213) in human plasma

1981 • 57 citations

The Cytological Effects of Podophyllin

1947 • 53 citations

Effects of a new antitumor agent, epipodophyllotoxin, on growth and chromosomes in human hematopoietic cell lines.

1973 • 53 citations

THE ACTION OF PODOPHYLLIN AND ITS FRACTIONS ON MARINE EGGS

1951 • 52 citations

Inhibition of etoposide-induced DNA damage and cytotoxicity in L1210 cells by dehydrogenase inhibitors and other agents.

1984 • 51 citations

Verapamil-induced augmentation of etoposide accumulation in L1210 cells in vitro.

1985 • 51 citations

Damage Induced in Sarcoma 37 with Podophyllin, Podophyllotoxin Alpha-Peltatin, Beta-Peltatin, and Quercetin<xref ref-type="fn" rid="fn1"><sup>2</sup></xref>

1950 • 50 citations

Tubulin binding affinities of podophyllotoxin and colchicine analogues.

1977 • 49 citations

Analysis of the anticancer drugs etoposide (VP 16-213) and teniposide (VM 26) by high-performance liquid chromatography with fluorescence detection

1981 • 49 citations

Inhibition by 4'-demethyl-epipodophyllotoxin 9-(4,6-O-2-thenylidene-beta-D-glucopyranoside) of human lymphoblast cultures in G2 phase of the cell cycle.

1975 • 48 citations

VP16-213 (Etoposide)

1982 • 48 citations

A comparative assessment of the in vitro effects of drugs on cells by means of colony assays or flow microfluorimetry

1981 • 48 citations

Free radical metabolism of VP-16 and inhibition of anthracycline-induced lipid peroxidation

1983 • 47 citations

The effect of dose on the bioavailability of oral etoposide

1986 • 47 citations

The effect of the two epipodophyllotoxin derivatives etoposide (VP-16) and teniposide (VM-26) on cell lines established from patients with small cell carcinoma of the lung

1987 • 47 citations

Potentiation of etoposide-induced DNA damage by calcium antagonists in L1210 cells in vitro.

1984 • 46 citations

Clinical investigation of a new podophyllum derivative, epipodophyllotoxin, 4'-demethyl-9-(4,6-O-2-thenylidene- -D-glucopyranoside) (NSC-122819), in patients with malignant lymphomas and solid tumors.

1972 • 45 citations

VP16-213 and podophyllotoxin

1982 • 44 citations

Comparative cytotoxic and cytokinetic effects of the epipodophyllotoxins 4'-demethylepipodophyllotoxin-9-(4,6-O-2-ethylidene-beta-D-glucopyranoside) and 4'-demethylepipodophyllotoxin-9-(4,6-O-2-thenylidene-beta-D-glucopyranoside) and their metabolites on human leukemic lymphoblasts.

1983 • 43 citations

Comparison of uptake and binding of two epipodophyllotoxin glucopyranosides, 4'-demethyl epipodophyllotoxin thenylidene-beta-D-glucoside and 4'-demethyl epipodophyllotoxin ethylidene-beta-D-glucoside, in the L1210 leukemia cell.

1978 • 42 citations

Phase I clinical trial of a new antitumor agent, 4'-demethylepipodophyllotoxin 9-(4,6-O-ethylidene- -D-glucopyranoside) (NSC-141540; VP-16-213).

1972 • 42 citations

Automated liquid chromatographic analysis of the anti-tumorigenic drugs etoposide (VP 16-213) and teniposide (VM 26)

1983 • 42 citations

Effect of Alpha-Peltatin, Beta-Peltatin, and Podophyllotoxin on Lymphomas and Other Transplanted Tumors<xref ref-type="fn" rid="fn1"><sup>2</sup></xref>

1950 • 41 citations

A sensitive high-performance liquid chromatographic method for determination of the anti-neoplastic agents vp 16-213 and vm 26 in biological fluids

1981 • 41 citations

Penetration of teniposide (VM-26) into human intracerebral tumors

1984 • 41 citations

Radiation recall associated with VP-16-213 therapy.

1979 • 39 citations

Analysis of 4′-demethylepipodophyllotoxin-9-(4,6-o-ethylidene-β-d-glucopyranoside) by high-pressure liquid chromatography

1980 • 38 citations

Plasma assay for the antineoplastic agent VP 16-213 (etoposide) using high-performance liquid chromatography with electrochemical detection

1983 • 38 citations

Analysis of the inhibitory effects of VP-16-213 (etoposide) and podophyllotoxin on thymidine transport and metabolism in Ehrlich ascites tumor cells in vitro.

1984 • 38 citations

Etoposide induced blood-brain barrier disruption in rats: duration of opening and histological sequelae.

1986 • 38 citations

PTG, a new antineoplastic epipodophyllotoxin

1975 • 36 citations

Microsomal interactions and inhibition of lipid peroxidation by etoposide (VP-16, 213): Implications for mode of action

1985 • 35 citations

Effects of verapamil on etoposide, vincristine, and adriamycin activity in normal human bone marrow granulocyte-macrophage progenitors and in human K562 leukemia cells in vitro.

1985 • 34 citations

The effect of food and concurrent chemotherapy on the bioavailability of oral etoposide

1985 • 34 citations

High-performance liquid chromatography of etoposide in plasma and urine

1985 • 34 citations

Etoposide—chemistry, preclinical and clinical pharmacology

1982 • 33 citations

Sedimentation of DNA from L1210 cells after treatment with 4'-demethylepipodophyllotoxin-9-(4,6-O-2-thenylidene-beta-D-glucopyranoside) or 1-beta-D-arabinofuranosylcytosine or both drugs.

1980 • 32 citations

Teniposide (VM-26)- and etoposide (VP-16-213)-induced augmentation of methotrexate transport and polyglutamylation in Ehrlich ascites tumor cells in vitro.

1982 • 32 citations

Current development of podophyllotoxins

1982 • 31 citations

Comparative study of early effects of epipodophyllotoxin derivatives and other cytostatic agents on mastocytoma cultures.

1977 • 30 citations

Clinical trial of the oral form of a new podophyllotoxin derivative, VP-16-213 (NSC-141540), in patients with advanced neoplastic disease.

1975 • 30 citations

In vitro cytotoxicity of VP 16 on primary tumor and metastasis of Lewis lung carcinoma

1982 • 29 citations

Phase II study of VM-26 in acute leukemia, neuroblastoma, and other refractory childhood malignancies: a report from the Children's Cancer Study Group.

1979 • 29 citations

Synthesis, 470-MHz proton NMR spectra, and activity of delactonized derivatives of the anticancer drug etoposide

1982 • 29 citations

Etoposide-induced blood-brain barrier disruption

1984 • 29 citations

Drug monitoring of etoposide (VP16-213)

1985 • 28 citations

Inhibition of NADH-linked respiration with the anti-cancer agent 4′-demethyl-epipodophyllotoxin thenylidene glucoside (VM-26)

1972 • 28 citations

High Performance Liquid Chromatography of Podophyllotoxins and Related Lignans

1981 • 27 citations

Pharmacokinetic evaluation of increasing dosages of etoposide in a chronic hemodialysis patient.

1985 • 27 citations

Teniposide (VM26) disposition in children with leukemia.

1984 • 27 citations

Pharmacokinetics and toxicity of the epipodophyllotoxin derivative etoposide (VP 16-213) in patients with gestational choriocarcinoma and malignant teratoma

1985 • 26 citations

ETOPOSIDE: A NEW ANTI-CANCER AGENT

1981 • 26 citations

Comparison of the biologic activity of VP-16-213 given iv and orally in capsules or drink ampules.

1976 • 26 citations

PHASE I clinical trial of an oral solution of VP-16-213.

1976 • 25 citations

Multicompartment Pharmacokinetic Model of 4′-Demethylepipodophyllotoxin 9-(4,6-O-Ethylidene- β-D-glucopyranoside) in Humans

1978 • 24 citations

Combination chemotherapy of the epipodophyllotoxin derivatives, Teniposide and Etoposide

1982 • 24 citations

Inactivation of φX174 DNA by the ortho-quinone derivative or its reduction product of the antitumor agent VP 16-213

1985 • 23 citations

A case report and description of the pharmacokinetic behavior of intrapleurally instilled etoposide

1985 • 23 citations

Pharmacokinetics of etoposide in gestochoriocarcinoma.

1985 • 23 citations

Phase I trial of a new form of an oral administration of VP-16-213.

1979 • 21 citations

Quantification of teniposide in human serum by high-performance liquid chromatography with electrochemical detection

1986 • 20 citations

Allergic reactions to teniposide in patients with neuroblastoma and lymphoid malignancies.

1985 • 20 citations

RATIONALE OF COMBINATION CHEMOTHERAPY

1980 • 20 citations

Comparison between VP 16 and VM 26 in Lewis lung carcinoma of the mouse

1986 • 19 citations

The Role of Drug Disposition Kinetics on Cellular Transport of the Antineoplastic Agent VM-26

1978 • 19 citations

The role of metabolic activation by cytochrome P-450 in covalent binding of VP 16-213 to rat liver and HeLa cell microsomal proteins

1985 • 18 citations

Metabolic studies of a podophyllotoxin derivative (VP16) in the isolated perfused liver

1985 • 18 citations

Flux of teniposide (VM-26) across the plasma membrane of teniposide-resistant sublines of L1210 cells.

1984 • 18 citations

Clinical studies with podophyllum compounds SPI-77 (NSC-72274) and SPG-827 (NSC-42076).

1966 • 18 citations

In vitro and in vivo metabolism of VP 16–213 in the rat

1982 • 17 citations

Autimitotic substances.

1968 • 17 citations

The Epipodophyllotoxin Derivatives VM-26 and VP-16-213, 1976–1979, a Review

1980 • 17 citations

Flow-cytometric analysis of DNA distribution after VP16-213 treatment of Lewis lung carcinoma

1983 • 17 citations

Pharmacokinetics of teniposide in patients with ovarian cancer.

1985 • 16 citations

Synergistic antitumor activity of vincristine and VP-16-213

1984 • 15 citations

Effect of Intracarotid Etoposide on Opening the Blood-Brain Barrier

1984 • 15 citations

Circadian rhythm in tolerance of mice for etoposide.

1985 • 15 citations

The effect of etoposide on human CFU-GM

1985 • 15 citations

Modification of the pendant ring of podophyllotoxin

1982 • 15 citations

Human anticancer effect of podophyllum derivatives (SPG and SPI): a preliminary report.

1967 • 15 citations

Radioimmunoassay for etoposide and teniposide

1985 • 14 citations

Interaction of VP16-213 with the DNA repair antagonist chloroquine

1982 • 14 citations

Pharmacokinetic Study of High Dose Etoposide Infusion in Patients with Small Cell Lung Cancer

1988 • 14 citations

High-performance liquid chromatographic determination of etoposide in plasma using electrochemical detection

1984 • 14 citations

Determination of etoposide (VP16-213) and teniposide (VM-26) in serum by high-performance liquid chromatography with electrochemical detection

1984 • 14 citations

Effects of the Epipodophyllotoxin Derivative VM 26 in Mitosis and in Interphase

1978 • 13 citations

Clinical and cell kinetic studies of the effects of the epipodophyllotoxin VP16-213 during therapy of refractory acute nonlymphocytic leukemia

1982 • 13 citations

VM26: Phase I and II studies

1982 • 13 citations

Etoposide infusions for treatment of metastatic lung cancer.

1984 • 12 citations

Antimetastasis effect of two derivatives of epipodophyllotoxin in mice

1976 • 12 citations

Etoposide (VP16-213) and teniposide (VM26) comparative in vitro activities in human tumors

1982 • 12 citations

Podophyllotoxin derivatives VP-16 and VM-26.

1987 • 11 citations

Pharmacokinetics of teniposide (VM 26) after IV administration in serum and malignant ascites of patients with ovarian carcinoma

1985 • 11 citations

A radioimmunoassay for VP16-213 in plasma

1982 • 11 citations

Partial Cross-Resistance of Cultured Murine Leukemia Vincristine-Resistant P388 Cells to 4'-Demethylepipodophyllotoxin Ethylidene- -D-Glucoside

1980 • 10 citations

Pharmacokinetic study of VM26 given as a prolonged IV infusion to ovarian cancer patients

1984 • 10 citations

Warfarin, etoposide, and vindesine interactions.

1984 • 9 citations

A Critical Review of its Activity

1982 • 7 citations

Absorption of Etoposide (VP-16-213) from the Small Intestine of the Rat. The Potential Role of Mucus as an Absorption Rate Limiting Barrier.

1985 • 6 citations

Determination of acetylator phenotype in hypertensive patients with renal impairment

1982 • 5 citations

Clinical pharmacology and intracerebral tumor penetration of 4'-demethyl epipodophyllotoxin 9-(4,6-O-ethylidene-β-D-glucopyranoside) (VP-16, NSC-141540)

1982 • 5 citations

Pharmacokinetics of VP16 in patients with impaired renal function

1985 • 5 citations

Comparison of pharmacokinetics of vp16 in mice, rats and humans. Abstr.

1983 • 5 citations

Clinical pharmacokinetics of VP16

1982 • 5 citations

A quantitative microdensitometric and autoradiographic study of the effect of 4?-demethyl-epipodophyllotoxin-?-D-thenylidene glucoside (VM-26) on the cell cycle of cultured fibroblasts

1979 • 4 citations

Uptake as a determinant of resistance to teniposide (vm-26). Abstr.

1983 • 3 citations

Clinical pharmacology of intracarotid etoposide

1986 • 3 citations

Free radical scavengers inhibit vp-16 induced dna damage and cytotoxicity. Abstr.

1983 • 3 citations

The effect of VP 16-213 on NBT reduction in the normal polymorphonuclear neutrophil.

1980 • 2 citations

A mammalian topoisomerase--possible relationship to intercalator-induced dna strand breakage. Abstr.

1981 • 2 citations

[Role of VM26 on glioma cells in vitro--analysis of G0 cells and recruitment (author's transl)].

1978 • 1 citations

Deleted Work

1955 • 0 citations